Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Background: although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy.
Design and methods: we compared the clinical and hematologic responses to change in %V617F (molecular response) in 73 patients with polycythemia vera treated with either interferon (rIFN?-2b: 28, Peg-rIFN?-2a: 18) or non-interferon drugs (n=27), which included hydroxyurea (n=8), imatinib (n=12), dasatinib (n=5), busulfan (n=1), and radioactive phosphorus (n=1). Hematologic response evaluation employed Polycythemia Vera Study Group criteria, and molecular response evaluation, European Leukemia Net criteria.
Results: of the 46 treated with interferon, 41 (89.1%) had a hematologic response, whereas only 7 (15.2%) had a partial molecular response. Of the 27 who received non-interferon treatments, 16 (59.3%) had a hematologic response, but only 2 (7.4%) had a molecular response. Median duration of follow up was 2.8 years. Statistical agreement between hematologic response and molecular response was poor in all treatment groups.
Conclusions: generally, hematologic response was not accompanied by molecular response. Therefore, a quantitative change in %V617F is not required for clinical response in patients with polycythemia vera
538-542
Kuriakose, Emil
6f356b9b-df4c-4c69-91ca-9d4978077606
Vandris, Katherine
42852a40-1f83-4d34-bd50-78dd60d14335
Wang, Y. Lynn
281a4bfb-c4f7-4bb1-b883-902d17f0e04c
Chow, William
d13aa895-54ab-47bf-b3b6-e3a62d8d098c
Jones, Amy V.
3d296088-a099-45cf-b227-541ff59d800c
Christos, Paul
5c7f4df0-2352-4477-a3f0-551cef8f1c25
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Silver, Richard T.
661e0b91-4a5c-4100-9a7a-e4f1db3f3a1d
April 2012
Kuriakose, Emil
6f356b9b-df4c-4c69-91ca-9d4978077606
Vandris, Katherine
42852a40-1f83-4d34-bd50-78dd60d14335
Wang, Y. Lynn
281a4bfb-c4f7-4bb1-b883-902d17f0e04c
Chow, William
d13aa895-54ab-47bf-b3b6-e3a62d8d098c
Jones, Amy V.
3d296088-a099-45cf-b227-541ff59d800c
Christos, Paul
5c7f4df0-2352-4477-a3f0-551cef8f1c25
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Silver, Richard T.
661e0b91-4a5c-4100-9a7a-e4f1db3f3a1d
Kuriakose, Emil, Vandris, Katherine, Wang, Y. Lynn, Chow, William, Jones, Amy V., Christos, Paul, Cross, Nicholas C.P. and Silver, Richard T.
(2012)
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.
Haematologica, 97 (4), .
(doi:10.3324/haematol.2011.053348).
(PMID:22102708)
Abstract
Background: although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear. The purpose of this study is to determine whether a reduction in %V617F in polycythemia vera is a prerequisite to achieving hematologic remission in response to cytoreductive therapy.
Design and methods: we compared the clinical and hematologic responses to change in %V617F (molecular response) in 73 patients with polycythemia vera treated with either interferon (rIFN?-2b: 28, Peg-rIFN?-2a: 18) or non-interferon drugs (n=27), which included hydroxyurea (n=8), imatinib (n=12), dasatinib (n=5), busulfan (n=1), and radioactive phosphorus (n=1). Hematologic response evaluation employed Polycythemia Vera Study Group criteria, and molecular response evaluation, European Leukemia Net criteria.
Results: of the 46 treated with interferon, 41 (89.1%) had a hematologic response, whereas only 7 (15.2%) had a partial molecular response. Of the 27 who received non-interferon treatments, 16 (59.3%) had a hematologic response, but only 2 (7.4%) had a molecular response. Median duration of follow up was 2.8 years. Statistical agreement between hematologic response and molecular response was poor in all treatment groups.
Conclusions: generally, hematologic response was not accompanied by molecular response. Therefore, a quantitative change in %V617F is not required for clinical response in patients with polycythemia vera
This record has no associated files available for download.
More information
Published date: April 2012
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 341950
URI: http://eprints.soton.ac.uk/id/eprint/341950
ISSN: 0390-6078
PURE UUID: aaa3cfc1-b5e6-4b0f-8124-7753ac245f74
Catalogue record
Date deposited: 08 Aug 2012 14:29
Last modified: 15 Mar 2024 03:11
Export record
Altmetrics
Contributors
Author:
Emil Kuriakose
Author:
Katherine Vandris
Author:
Y. Lynn Wang
Author:
William Chow
Author:
Amy V. Jones
Author:
Paul Christos
Author:
Richard T. Silver
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics